R292K substitution and drug susceptibility of influenza A(H7N9) viruses. - Wikidata - awgldk - TriplyDB

R292K substitution and drug susceptibility of influenza A(H7N9) viruses.

R292K substitution and drug susceptibility of influenza A(H7N9) viruses.

http://www.wikidata.org/entity/Q37262432

about

Amantadine and rimantadine for influenza A in children and the elderly Clinical Implications of Antiviral Resistance in Influenza Use of highly pathogenic avian influenza A(H5N1) gain-of-function studies for molecular-based surveillance and pandemic preparedness.The pharmacological management of severe influenza infection - 'existing and emerging therapies'.Avian influenza virus in pregnancy.Mammalian models for the study of H7 virus pathogenesis and transmission.Influenza virus A/Anhui/1/2013 (H7N9) replicates efficiently in the upper and lower respiratory tracts of cynomolgus macaques.Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses The pandemic potential of avian influenza A(H7N9) virus: a review.Translational research on influenza virus infection using a nonhuman primate model.A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals.An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.PCR for detection of oseltamivir resistance mutation in influenza A(H7N9) virus An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality.Mutations of novel influenza A(H10N8) virus in chicken eggs and MDCK cells.Detection sensitivity of influenza rapid diagnostic tests Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution.Poultry farms as a source of avian influenza A (H7N9) virus reassortment and human infection.The R292K mutation that confers resistance to neuraminidase inhibitors leads to competitive fitness loss of A/Shanghai/1/2013 (H7N9) influenza virus in ferrets.Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.Peramivir: an intravenous neuraminidase inhibitor.H7N9 avian influenza A virus in China: a short report on its circulation, drug resistant mutants and novel antiviral drugs.Discovery of potential drugs for human-infecting H7N9 virus containing R294K mutation.Role of R292K mutation in influenza H7N9 neuraminidase toward oseltamivir susceptibility: MD and MM/PB(GB)SA study.Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9).Differences in the epidemiology and virology of mild, severe and fatal human infections with avian influenza A (H7N9) virus.Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.

P2860

Q24187883-E1B9E879-F098-4D18-A647-D2584208AE6C Q26782746-68FF8894-4E59-463E-9A04-66BE32F7AFBF Q30205712-66CAB352-230D-43E6-A324-C1B6D8F1B83E Q30243907-66C6E7D8-7B0A-43C8-8461-A979E05243F0 Q30250287-B452BA52-0B73-45DE-88E8-C354A59A51CF Q30364385-AE7F3F20-B84E-4983-B265-9861782D85A1 Q30365646-1E149379-B0C7-4AC7-80AB-D1B9100C84C2 Q30372421-244E0156-6B83-4125-9060-813BFF37BF91 Q30377088-C2266DA1-97EA-40B6-A838-F25DB0D8C75D Q30383873-8D2E274A-B9B4-4CAC-8A5C-9ED9DF96827D Q30390167-633AF4F1-8EA5-46C4-8CE5-48ECE625D1C4 Q30401424-60C48E70-2788-4EF7-B41B-9A7C0E9A9945 Q30571702-6744CDBB-053C-4D42-9E65-2B615EF900BF Q33577183-68B51EC2-FE8D-4FFD-9C9F-D26BF10A3334 Q33880235-A400F4AC-8D90-40EB-B105-738E20DA5D28 Q34259910-633F708B-4BC4-40F8-A83D-6E83DE0B4C7E Q34381616-F25B6503-E085-4899-9798-7EBEBEDA03E2 Q34597785-44190BDB-76E8-4341-94FD-9026CEAC1120 Q34762862-6F9F1007-C209-4C10-BF19-D48218E24F28 Q34969729-28AAEAE6-FC64-4542-8E74-59944518A1EA Q34974802-05144497-4260-47EF-8481-B506A502C387 Q35076812-66DFB2C9-8DCB-4433-AD1C-925A1640C192 Q35640944-03DE31D5-2253-4BBE-BD93-98F0095677BE Q35860081-E582D8CC-227F-4AD6-9FD1-8C98E20FDDD8 Q36730084-6571C5B9-37C0-4FC1-8F4B-7C6DE0326413 Q37394266-5D7317FD-1842-4744-A583-5A00189FC430 Q38543777-91B5633B-9A39-4EC5-B503-E6097C8071D9 Q38686514-A781C395-09F0-490B-862B-BC1585B6D6DE Q39079415-16DB1EA2-E049-48C6-B981-B489D633AB40 Q40513178-3BFFFDE6-7834-4B54-9913-C5A1AFE1DB30 Q40644333-5888F6A7-E717-43B0-80AB-AAF15C7EE7F6 Q40787287-8C76479E-E19E-44BF-AE30-978BDDD524FD Q41932777-69250EF0-81AD-45FA-9399-6432FAEC03EE Q42199847-87596043-8EC6-40D2-9394-B434A8BC0E70

P2860

R292K substitution and drug susceptibility of influenza A(H7N9) viruses.

http://www.wikidata.org/entity/Q37262432

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

R292K substitution and drug susceptibility of influenza A

@nl

R292K substitution and drug susceptibility of influenza A(H7N9) viruses.

@en

type

label

R292K substitution and drug susceptibility of influenza A

@nl

R292K substitution and drug susceptibility of influenza A(H7N9) viruses.

@en

prefLabel

R292K substitution and drug susceptibility of influenza A

@nl

R292K substitution and drug susceptibility of influenza A(H7N9) viruses.

@en

P1433

Q37262432-B59BF939-59F9-4984-B913-CE3275EE57BC

P1476

Q37262432-28FBF1F7-ED50-4B64-82E1-B6B63AEE29C2

P2093

Q37262432-3E830990-4056-432B-866E-AAD13DAFDADE

Q37262432-4514F0CB-5139-40FC-A8F3-2B419806F5C6

Q37262432-73CE0B10-DB1E-4DF7-AF8C-395ACDBBF369

Q37262432-95FBC3C5-BA12-4D63-9692-64D3616A779C

Q37262432-C19F5FF9-6412-4A9B-8982-543B9212645A

Q37262432-CD10FEC5-DDF0-49ED-8B8A-B9C55631F75A

P2860

Q37262432-1F918880-437D-496D-86EC-04155F4ECB42

Q37262432-59259645-541C-4B45-BAED-23843397E0F9

Q37262432-5D2915CB-4E3D-4DCB-A7AC-32728D44F187

Q37262432-6DDD5502-692E-43D1-84CC-795D235F6985

Q37262432-72E1E2D9-A111-4899-A619-AA7FA79828E3

Q37262432-75C7EF90-F305-448B-921F-AC367A8D4FC1

Q37262432-7920618F-1436-4C58-92AF-DE4D7050A990

Q37262432-85E72906-0398-4072-B76A-81E5B76D3A50

Q37262432-AC7361A7-E492-444F-A573-3A3782C32E89

Q37262432-AE40AED8-42D0-4067-8B0B-98A88B95F400

P304

Q37262432-0BA2B783-D60D-46CE-B540-CACA3EFFB271

P31

Q37262432-99FD7B35-3009-45BE-8700-805CE72E34F1

P356

Q37262432-DDCCD3EB-8C87-48EF-AB1E-954D3141F05A

P433

Q37262432-61A68A53-90E4-4FE3-AB67-13FB627D3413

P478

Q37262432-B6BFC407-358A-48AA-B4D6-00825750AC9E

P577

Q37262432-CA7F8FF6-05F8-4F2E-99DE-1ACCF50715BE

P5875

Q37262432-10CD35C8-5B0F-41BB-9C50-AF5C8397F557

P698

Q37262432-6F129899-2E81-4AA4-B0C3-9404B0085ED8

P932

Q37262432-FA7C08ED-5970-414C-88D0-3C4A9556A233

P356

P1433

Emerging Infectious Diseases

P1476

R292K substitution and drug susceptibility of influenza A(H7N9) viruses.

@en

P2093

James Stevens

http://www.w3.org/2001/XMLSchema#string

John Barnes

http://www.w3.org/2001/XMLSchema#string

Katrina Sleeman

http://www.w3.org/2001/XMLSchema#string

Larisa V Gubareva

http://www.w3.org/2001/XMLSchema#string

Michael Shaw

http://www.w3.org/2001/XMLSchema#string

Zhu Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Human infection with a novel avian-origin influenza A (H7N9) virus

Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.

Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.

Resistance of influenza viruses to neuraminidase inhibitors--a review.

Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model.

Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.

Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.

Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets.

Emergence of avian influenza A(H7N9) virus causing severe human illness - China, February-April 2013.

Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.

P304

1521-1524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3201/EID1909.130724

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256072616

http://www.w3.org/2001/XMLSchema#string

P698

23965618

http://www.w3.org/2001/XMLSchema#string

P932

3810934

http://www.w3.org/2001/XMLSchema#string